Usefulness of cytosolic tissue-type plasminogen activator levels in lung adenocarcinomas

Medicina Clinica

Volumn 119, Issue 1, 2002, Pages 1-3

  Ruibal Morell, álvaro ^a   Núñez, Matilde Isabel ^a   del Río, Mari Carmen ^b   Rodríguez, Jesús ^c   álvarez de Linera, José Feliciano ^c  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b UNIVERSIDAD ALFONSO X EL SABIO   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Cytosol; Lung adenocarcinomas; Tissue type plasminogen activator (t PA)

Indexed keywords

CA 125 ANTIGEN; CATHEPSIN D; CD44V ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; HYALURONIC ACID; NEURON SPECIFIC ENOLASE; ONCOPROTEIN; PROTEIN PS2; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER TISSUE; CELL CYCLE S PHASE; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PLOIDY; PROGNOSIS; TUMOR VOLUME; ADENOCARCINOMA; LUNG TUMOR; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; CYTOSOL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037042698     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(02)73295-8     Document Type: Article

References (29)

1. Plasminogen activators and cancer
2. Tissue-type plasminogen activator, a new prognostic marker in breast cancer
3. Fibrinolytic pathway and the endothelium
4. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator
5. Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas
6. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors
7. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression
8. Significance of plasminogen activator inhibitor as a prognostic marker in primary lung cancer: Association of decreased plasminogen activator inhibitor 2 with lymph node metastasis
9. The urokinase type plasminogen activator system in resected non small cell lung cancer
10. Alterations to the fibrinolytic enzyme system in patients with non-small cell lung carcinoma
11. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination
12. Tissue type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa: Relationship with clinicopathological parameters and prognostic significance
13. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer
14. Tissue-type plasminogen activator induced invasion and metastasis of murine melanomas
15. Cytosolic tissue-type plasminogen activator (t-PA) levels in ductal infiltrating carcinomas of the breast classified according to different clinical and biological parameters
16. Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer
17. Cytosolic tissue-type plasminogen activator (t-PA) levels in breast tumors and hormone dependence. Role of p2
18. Analysis of expression of components in the plasminogen activator system in high and low metastatic human lung cancer cells
19. Comparison of imunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumor tissue
20. Immunohistochemical localization of cioagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung
21. Serum tumor marker CA125 in monitoring of ovarian cancer during first-line chemotherapy
22. Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen CA125, and CA50 cytosolic content in non-small cell lung cancer
23. Analysis of the prognostic significance of cytosolic determination of CA125 tumor associated antigen, carcinoembryonic antigen and squamous cell carcinoma antigen in patients with non small cell lung carcinoma
24. Concordance between serum and cytosolic levels of CEA, CA125 and SCC antigens in patients with non small cell lung cancer
25. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small cell lung cancer
26. The molecular and cellular basis of human lung cancer
27. The molecular biology of lung cancers. Application to early detection and prevention
28. C-erbB2 expression and codon 12 k-ras mutations both predicts shortened survival for patients with pulmonary adenocarcinoma
29. Up-regulation of urokinase type plasminogen activator expression by the HER2/neu proto-oncogene